Neoral and Sofosbuvir

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

Coadministration with cyclosporine may significantly increase the plasma concentrations of sofosbuvir, but appears to have little effect on the pharmacokinetics of the predominant metabolite, GS-331007. The proposed mechanism is cyclosporine inhibition of the P-glycoprotein-mediated intestinal efflux of sofosbuvir. In 19 healthy study subjects administered a single 400 mg dose of sofosbuvir in combination with a single 600 mg dose of cyclosporine, mean sofosbuvir peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 2.5- and 4.5-fold, respectively. In contrast, mean Cmax of GS-331007 decreased by 40%, while AUC remained unchanged, which is consistent with the fact that GS-331007 is not a substrate of P-glycoprotein. Because GS-331007 is the predominant circulating entity following administration of sofosbuvir, accounting for greater than 90% of drug-related material systemic exposure, this interaction is unlikely to be of clinical significance.

Neoral

Generic Name: cyclosporine

Brand name: Gengraf, Neoral, Sandimmune, Sandimmune

Synonyms: Neoral (Capsules, Modified)

What is Neoral?

Sofosbuvir

Generic Name: sofosbuvir

Brand name: Sovaldi

Synonyms: n.a.

What is Sofosbuvir?